Literature DB >> 19242801

Outcome of retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin.

Nilesh Mehta1, Uma K Murthy, Vivek Kaul, Samuel Alpert, Gerald Abruzzese, Charles Teitelbaum.   

Abstract

The purpose of this study is to evaluate the incidence and outcome of retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin. A total of 74 hepatitis C patients with baseline eye exams and eye exams during therapy were included. Retinopathy was defined as development of cotton wool spots and/or intra-retinal hemorrhage. Demographics, hepatitis C viral characteristics, treatment and laboratory data, and eye exam findings were compared in groups with and without retinopathy. Retinopathy developed in 28 (38%), early in therapy. Pre-treatment eye exams did not predict risk of retinopathy. Therapy was continued in all but one; cotton wool spots resolved in 24 of 26. All nine patients with intra-retinal hemorrhage had resolution. No patient had retinopathy-related visual deterioration. Retinopathy is common with peginterferon therapy, but the outcome is favorable. Cessation of therapy for retinopathy is not warranted. Severe visual disturbances and scotomas deserve further evaluation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19242801     DOI: 10.1007/s10620-009-0721-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  15 in total

1.  Clinical characteristics of hepatitis C virus-associated retinopathy.

Authors:  T Abe; A Nakajima; N Satoh; T Koizumi; S Sakuragi; T Ono; M Komatsu; O Masamune
Journal:  Jpn J Ophthalmol       Date:  1995       Impact factor: 2.447

2.  Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  Chiaki Okuse; Hiroshi Yotsuyanagi; Yoshihiko Nagase; Yuhtaro Kobayashi; Kiyomi Yasuda; Kazuhiko Koike; Shiro Iino; Michihiro Suzuki; Fumio Itoh
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

3.  Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation.

Authors:  J A Chisholm; G Williams; E Spence; S Parks; D Keating; M Gavin; P R Mills
Journal:  Aliment Pharmacol Ther       Date:  2005-03-15       Impact factor: 8.171

4.  Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center.

Authors:  M E Briggs; C Baker; R Hall; J M Gaziano; D Gagnon; N Bzowej; T L Wright
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

5.  Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.

Authors:  K Jain; W C Lam; S Waheeb; Q Thai; J Heathcote
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

6.  Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C.

Authors:  H Saito; H Ebinuma; H Nagata; Y Inagaki; Y Saito; K Wakabayashi; T Takagi; M Nakamura; H Katsura; Y Oguchi; H Ishii
Journal:  Liver       Date:  2001-06

7.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

8.  Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis.

Authors:  Louis d'Alteroche; Samuel Majzoub; Anne-Isabelle Lecuyer; Marie-Paule Delplace; Yannick Bacq
Journal:  J Hepatol       Date:  2005-08-18       Impact factor: 25.083

9.  Retinal complications during interferon therapy for chronic hepatitis C.

Authors:  T Kawano; M Shigehira; H Uto; T Nakama; J Kato; K Hayashi; T Maruyama; T Kuribayashi; T Chuman; T Futami; H Tsubouchi
Journal:  Am J Gastroenterol       Date:  1996-02       Impact factor: 10.864

10.  Is screening for interferon retinopathy in hepatitis C justified?

Authors:  F M Cuthbertson; M Davies; M McKibbin
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

View more
  7 in total

Review 1.  Ophthalmologic complications of antiviral therapy in hepatitis C treatment.

Authors:  Roderick O'Day; Mark C Gillies; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 2.  Toxic hepatitis in occupational exposure to solvents.

Authors:  Giulia Malaguarnera; Emanuela Cataudella; Maria Giordano; Giuseppe Nunnari; Giuseppe Chisari; Mariano Malaguarnera
Journal:  World J Gastroenterol       Date:  2012-06-14       Impact factor: 5.742

Review 3.  Environmental Toxicants and NAFLD: A Neglected yet Significant Relationship.

Authors:  Sangam Rajak; Sana Raza; Archana Tewari; Rohit A Sinha
Journal:  Dig Dis Sci       Date:  2021-08-12       Impact factor: 3.487

4.  A Drop in Hemoglobin as an Association with Pegylated Interferon Retinopathy: A Novel Pathophysiology.

Authors:  Meghan Berkenstock; Shaivi Patel; Jessica Ackert
Journal:  J Curr Ophthalmol       Date:  2020-04-30

Review 5.  Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C.

Authors:  Ji-Hua Xue; Hai-Hong Zhu; Jing Wang; Zhi Chen
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 6.  The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C.

Authors:  Christine Hong Ting Yang; Eric R Yoo; Aijaz Ahmed
Journal:  J Clin Transl Hepatol       Date:  2017-02-07

7.  Prospective study of clinical characteristics of melanoma patients with retinopathy caused by a high-dose interferon α-2b.

Authors:  Shijie Lan; Zhihua Cui; Qiliang Yin; Zhigang Liu; Lingling Liang; Hua He; Hesong Liu; Zhen Guo; Yingying Yu; Di Wu
Journal:  Melanoma Res       Date:  2021-12-01       Impact factor: 3.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.